Our study also identified several enriched pathways and gene signatures specific to EμMyc/Casp2−/− or Th-MYCN/Casp2−/− tumors that may be associated with enhanced EμMyc-induced lymphomas and/or delayed Th-MYCN-mediated neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.